23andMe Holding Co (23andMe Holding Co) Quality Rank

View and export this data going back to 2021. Start your Free Trial

What is 23andMe Holding Co Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

23andMe Holding Co Quality Rank Related Terms

Thank you for viewing the detailed overview of 23andMe Holding Co's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

23andMe Holding Co (23andMe Holding Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » 23andMe Holding Co (NAS:ME) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

349 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.23andme.com

23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment include Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.

Executives

Kathy L Hibbs	officer: See Remarks	C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
William G Richards	officer: Head of Therapeutics Discovery	160 KELLY AVE, HALF MOON BAY CA 94019
Richard H Scheller	director	C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990
Joseph Anthony Selsavage	officer: Interim CFO	490 HILL STREET, APT 5, SAN FRANCISCO CA 94114
Kenneth J. Hillan	officer: Head of Therapeutics	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Evan Lovell	director, officer: Chief Financial Officer	27 SOUTH PARK STREET, SUITE 200, SAN FRANCISCO CA 94107
Hernandez Sandra R Md	director	BLACKBAUD INC, 2000 DANIEL ISLAND DRIVE, CHARLESTON SC 29492
Paul D Johnson	officer: VP, General Manager-Consumer	440 N BARRANCA AVE #3550, COVINA CA 91723
Tracy Keim	officer: See Remarks	6107 ARROWROOT LANE, RANCHO PALOS VERDES CA 90275
Steven Lemon	officer: Vice President, Engineering	1020 CHERRY AVENUE, SAN JOSE CA 95125
Steven J Schoch	officer: See Remarks	2748 BUSH STREET, SAN FRANCISCO CA 94115
Frederick Mark Kohler	officer: Vice President, People	1004 UNION STREET, ALAMEDA CA 94501
Sequoia Capital Global Growth Ii Principals Fund, L.p.	10 percent owner	2800 SAND HILL ROAD, SUITE 101, MENLO PARK CA 94025
Abeec 2.0, Llc	10 percent owner	171 MAIN STREET, SUITE 259, LOS ALTOS CA 94022
Anne Wojcicki	director, 10 percent owner, officer: Chief Executive Officer	C/O AJAX I HOLDINGS, LLC, 667 MADISON AVENUE, NEW YORK NY 10606